Sustaining Remission From PTSD Using Tuned Vibroacoustic Stimulation (TVS) Following MDMA-Assisted Psychotherapy

This supportive care trial (n=200) will investigate the sustained remission from posttraumatic stress disorder (PTSD) using Tuned Vibroacoustic Stimulation (TVS) following MDMA-assisted psychotherapy.

The study, sponsored by Apollo Neuroscience, Inc., aims to assess the effect of the Apollo wearable device on individuals who have undergone MDMA-assisted psychotherapy for PTSD.

Participants will receive the Apollo wearable device, which emits gentle vibrations, and will be instructed to use it regularly for two years following their psychotherapy sessions. The primary objective is to determine if the regular use of the Apollo device improves rates of sustained symptom remission in PTSD following MDMA-assisted psychotherapy. The study will involve completing monthly online questionnaires to monitor outcomes related to PTSD symptoms, depression, anxiety, emotion regulation, work performance, alcohol and drug use, and chronic pain.

Participants aged 18 and older who have completed the MAPS MDMA-Assisted Psychotherapy for PTSD clinical trial are eligible to participate. The study commenced on December 8, 2021, and is estimated to be completed by December 31, 2025.

Topic PTSD
Compound MDMA
Country United States of America
Visit trial
Status Recruiting
Results Published No
Start date 08 December 2021
End date 31 December 2025
Phase Not Applicable
Design Open
Type Interventional
Generation First
Participants 200
Sex All
Age 18- 99
Therapy Yes

Trial Details

The purpose of this research is to examine a wearable device called Apollo that emits gentle vibrations found to benefit mood, energy, and focus. We want to understand how it affects outcomes related to MDMA-assisted psychotherapy for PTSD including depression, anxiety and emotion regulation. This study will test whether regular use of the Apollo wearable improves rates of sustained symptom remission in PTSD following MDMA-assisted psychotherapy over the course of two years.

NCT Number NCT05274230

Sponsors & Collaborators

Apollo Neuro
Apollo Neuroscience is a company focused on developing wearable technology that actively enhances health by using touch therapy.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.